Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement-Reference-Cited by-同舟云学术

Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement

Published:2020-07-10 Issue:12 Volume:61 Page:2980-2984
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Furqan Fateeha¹,Watson Grace¹,Samaniego Felipe¹,Fayad Luis E.¹,Rashmi Kanagal-Shamanna ²^ORCID,Morrison Michael W.¹,Thompson Philip A.³,Steiner Raphael E.¹^ORCID,Chi Linda⁴,Dabaja Bouthaina⁵,Pinnix Chelsea C.⁵^ORCID,Neelapu Sattva S.¹,Nastoupil Loretta J.¹,Strati Paolo¹

Affiliation:

1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4. Department of Neuro-Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Funder

MD Anderson Cancer Center

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1791849

Reference17 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

2. Low grade b-cell non-Hodgkin lymphomas (NHL) involving the central nervous system (CNS): An analysis from the National Cancer Database (NCDB).

3. Extranodal Marginal Zone Lymphoma of the Central Nervous System

4. Central nervous system manifestations of marginal zone B-cell lymphoma

5. Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary central nervous system marginal zone lymphoma;British Journal of Haematology;2023-12-06

2. Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?;BLOOD RESEARCH;2021-12-31

3. Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma;Expert Opinion on Pharmacotherapy;2021-06-21